🔎 Trials Near Me

Home › Macular Degeneration › Oregon › Eugene

Macular Degeneration clinical trials in Eugene, OR

5 studies for Macular Degeneration are looking for participants at sites in and around Eugene (within about 30 miles). Open a study to see who can join and how to contact the study team.

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

RecruitingPhase 3
  • Verum Research LLC, Eugene
  • Cascade Medical Research Institute LLC, Springfield · 3 mi away
Ages 50 to 85 · All sexes · Updated Sep 18, 2026 · NCT06541704

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

RecruitingPhase 2/3
  • Verum Research LLC, Eugene
  • Cascade Medical Research Institute, LLC, Springfield · 3 mi away
Ages 60 and older · All sexes · Updated Sep 14, 2026 · NCT06635148

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

RecruitingPhase 1/2
  • Verum Research, LLC, Eugene
Ages 50 and older · All sexes · Updated Aug 21, 2026 · NCT05197270

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)

RecruitingPhase 2/3
  • Cascade Medical Research Institute, LLC, Springfield · 3 mi away
Ages 50 and older · All sexes · Updated Aug 6, 2026 · NCT07496567

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

RecruitingPhase 3
  • Verum Research, LLC, Eugene
Ages 50 and older · All sexes · Updated Apr 16, 2026 · NCT07064759

About Macular Degeneration

Macular degeneration, or age-related macular degeneration (AMD), causes vision loss in older adults. Learn about the types and what can help.

More about Macular Degeneration on MedlinePlus

Macular Degeneration trials in other cities

Other studies in Eugene

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.